|
| |
|
|
Arthrosurface, Inc. was organized to develop surgical alternatives for the treatment of orthopedic joint disease. Arthrosurface's initial efforts have resulted in the development of a new method to repair isolated articular cartilage defects and damage to major joints including the knees, hips and shoulders using minimal access surgical procedures. |
|
|
| |
|
|
Athenix provides genes, proteins, traits, and transgenic organisms for multiple industry sectors including agricultural chemicals, specialty chemicals, seed, industrial enzymes, feed, and energy. |
|
|
| |
|
|
CardioMEMS, Inc. is a medical device company focused on the application of Microelectromechanical systems (MEMS) technology to create innovative devices for the diagnosis, treatment and management of chronic diseases. CardioMEMS is developing an implantable wireless sensor targeted for the Abdominal Aortic Aneurysm (AAA) and Congestive Heart Failure (CHF) markets. |
|
|
| |
|
|
Coapt Systems, Inc is developing novel soft-tissue fixation technology with a wide range of applications in plastic orthopedic surgery. Featuring MultiPoint™ technology, Coapt's manufactures and markets bioabsorbable implants that reliably place and shape soft tissue without sutures, pins, or screws. |
|
|
| |
|
|
Collegium is an early stage specialty pharmaceutical company focused on the development of proprietary, late stage pharmaceutical products for the rapidly growing reformulation market and related areas. |
|
|
| |
|
|
CombinatoRx, Incorporated (NASDAQ: CRXX) is a biopharmaceutical company focused on developing new medicines built from synergistic combinations of approved drugs, designed to attack disease on multiple fronts. CombinatoRx applies its proprietary combination drug discovery technology to identify new combination product candidates in a number of disease areas, including immunoinflammatory disease, oncology, metabolic disease, neurodegenerative disease, and infectious disease. |
|
|
| |
|
|
EpiGenesis Pharmaceuticals is a drug discovery and development company focused on respiratory disease. The company has a promising Phase I candidate for asthma, EPI 12323, which is an inhaled steroid with unique properties and early indications that it could outperform current steroid treatments on the market. |
|
|
| |
|
|
EPIX Pharmaceuticals, formed from the merger of Predix Pharmaceuticals and Epix Pharmaceuticals, is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients.
|
|
|
| |
|
|
GlycoFi is developing a novel protein production platform that will revolutionize the biopharmaceutical industry. By humanizing the glycosylation of yeast and filamentous fungi, GlycoFi will facilitate the development of new protein based therapies. |
|
|
| |
|
|
Histogenics Corporation expertise and focus is on repairing articular cartilage damage utilizing advancements in cell biology, tissue culture, engineering, and materials science to affect tissue repair. |
|
|
| |
|
|
ILEX is a public drug development company focused exclusively on anti-cancer agents. The company leverages its expertise in identification, development, manufacturing, and regulatory approval process of oncology drugs to develop cancer therapeutics, build a chemoprevention product platform, and serve as a value added provider of contract development services (Nasdaq: ILXO). |
|
|
| |
|
|
Novalar is developing a drug agent that is designed to reverse the effects of local anesthesia applied in dental procedures, thereby allowing patients to return to their daily activities without the speech impediments, lip biting, and difficulty in eating that can be caused by unintended soft-tissue anesthesia. |
|
|
| |
|
|
Sapphire Therapeutics (Sapphire) is a privately held biopharmaceutical company committed to developing and commercializing promising compounds that are ready for clinical or preclinical testing in oncologic and metabolic diseases. |
|
|
| |
|
|
Tektagen is a private product development laboratory providing testing, development, and validation services to the pharmaceutical and biotechnology markets based in Pennsylvania. Sold to Charles River Laboratories, a division of Bausch & Lomb, in March, 1998 (NYSE: BOL). |
|
|
Boston Millennia Partners’ portfolio reflects Millennia’s commitment towards building enduring, large-scale businesses that have the potential to provide superior financial returns to our investors. Millennia’s portfolio is comprised of a diversified group of firms each positioned with the potential to become leaders in their respective market segments. We invite you to use the links below to learn more about each of those portfolio companies.
